ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO21

The Hepatorenal Fibrocystic Disease Core Center

Session Information

Category: Genetic Diseases of the Kidneys

  • No subcategory defined

Authors

  • Mrug, Michal, The University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Guay-Woodford, Lisa M., Children's National Health System, Washington, District of Columbia, United States
  • Parant, John M., The University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Yoder, Bradley K., The University of Alabama at Birmingham, Birmingham, Alabama, United States
Description

The Hepatorenal Fibrocystic Disease Core Center (HRFDCC) is an established interdisciplinary Center with a unique focus on Autosomal Recessive Polycystic Kidney Disease (ARPKD) and other single gene recessive HRFD disorders (NPHP, MKS, BBS, JBTS, OFD, etc.). The Center provides opportunities for integrating the unique research and clinical expertise that are represented by each of its Cores. Further, the HRFDCC coordinates training and research opportunities with multiple NIH and University Centers including the UAB/UCSD O’Brien Center, UAB Nephrology Research and Training Center, and the Clinical and Translational Science Award (CTSA) programs at each institution. This allows the Center to expand activities far beyond that possible with only the P30 support. The overarching goals of the HRFDCC are: 1) to attract and support new scientific expertise and research into causes of HRFDs; 2); to facilitate the use of scientifically rigorous, state-of-the-art methodologies in a cost-effective manner to address HRFD pathogenesis; 3) to expand capabilities and specificity of diagnostic tools associated with HRFDs; and 4) to promote testing and development of efficacious treatments for HRFDs.

Funding

  • NIH-NIDDK